Dowling & Yahnke LLC Oncternal Therapeutics, Inc. Transaction History

Dowling & Yahnke LLC

$215 Million
Q3 2022

A detailed history of Dowling & Yahnke LLC transactions in Oncternal Therapeutics, Inc. stock. As of the latest transaction made, Dowling & Yahnke LLC holds 150,464 shares of ONCT stock, worth $170,024. This represents 0.06% of its overall portfolio holdings.

Number of Shares

150,464

Previous 150,464 -0.0%

Holding current value

$170,024

Previous $167,000 19.76%

% of portfolio

0.06%

Previous 0.01%

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	BUY	$2.49 - $4.39 $62,675 - $110,500	25,171 Added 20.09%	150,464 $441,000
Q4 2019 Jan 27, 2020	SELL	$3.75 - $6.11 $25,653 - $41,798	-6,841 Reduced 5.18%	125,293 $495,000
Q3 2019 Oct 29, 2019	BUY	$3.87 - $6.13 $511,358 - $809,981	132,134 New	132,134 $661,000

Others Institutions Holding ONCT

# of Institutions

Shares Held

362K

Call Options Held

Put Options Held

View Full List

About Oncternal Therapeutics, Inc.

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $62.7M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

More about ONCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dowling & Yahnke LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dowling & Yahnke LLC with notifications on news.

Account

Dowling & Yahnke LLC Oncternal Therapeutics, Inc. Transaction History